Get started
Work

The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model

Year: 2022
Type: article
Abstract: This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infectionin vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and perforin/granzyme B and synergistically enhances autologous NK and CD8 cells’ killing of target cells.
DOI: 10.1128/jvi.01730-22
Authors: Aswath P. Chandrasekar, Nathan W. Cummins, Sekar Natesampillai, Anisha Misra, Alecia Alto, Greg Laird, Andrew D. Badley
Institution: Mayo Clinic
Language: English
Subfield: Virology
Open Access status: hybrid
Awards: G1896443692, G382303610, Prime shock and kill for HIV erradication, G521733456, Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs, G6340876455, ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIV
OpenAlex ID: W4310398275
FWCI: 1.876
Cites: 81
Cited by: 29
Related to: 10